Get the Stockscreener App
7.18
0.00%
0.00
After Hours:
7.20
0.02
+0.28%
Xeris Biopharma Holdings Inc stock is traded at $7.18, with a volume of 944.53K.
It is up +0.00% in the last 24 hours and down -22.21% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$7.18
Open:
$7.23
24h Volume:
944.53K
Relative Volume:
0.41
Market Cap:
$1.19B
Revenue:
$246.03M
Net Income/Loss:
$-32.00M
P/E Ratio:
-33.79
EPS:
-0.2125
Net Cash Flow:
$-16.78M
1W Performance:
+5.12%
1M Performance:
-22.21%
6M Performance:
+50.21%
1Y Performance:
+108.12%
1-Day Range:
$7.10
$7.24
1-Week Range:
$6.80
$7.24
52-Week Range:
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.18 | 1.19B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | H.C. Wainwright | Buy |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
What drives Xeris Biopharma Holdings Inc 2B30 stock priceDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns - Markets Mojo
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockIndex Update & Accurate Entry/Exit Alerts - newser.com
Will Xeris Biopharma Holdings Inc. (2B30) stock hit Wall Street targetsPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Will Xeris Biopharma Holdings Inc. stock deliver long term returns2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Detecting support and resistance levels for Xeris Biopharma Holdings Inc.2025 Year in Review & Verified Stock Trade Ideas - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsJuly 2025 Rallies & Daily Chart Pattern Signals - newser.com
Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade - Sahm
What high frequency data says about Xeris Biopharma Holdings Inc.2025 Support & Resistance & Risk Controlled Swing Alerts - newser.com
How sentiment analysis helps forecast Xeris Biopharma Holdings Inc.Trade Volume Report & Long-Term Safe Investment Ideas - newser.com
How Raised 2025 Revenue Guidance and Q3 Profitability Will Impact Xeris Biopharma (XERS) Investors - Sahm
Hecht Beth, chief legal officer, sells Xeris Biopharma (XERS) shares for $123k - Investing.com India
Officer Hecht Files To Sell 66,668 Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Is Xeris Biopharma Holdings Inc. (2B30) stock supported by strong fundamentalsIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendationsTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Is Xeris Biopharma Holdings Inc. (2B30) stock cheap vs fundamentalsJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - newser.com
Is a relief rally coming for Xeris Biopharma Holdings Inc. holdersStock Surge & Community Consensus Stock Picks - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Is Xeris Biopharma Holdings Inc. stock entering bullish territoryJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Applying chart zones and confluence areas to Xeris Biopharma Holdings Inc.Oil Prices & Consistent Growth Equity Picks - newser.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
Q4 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma (XERS) Turns Profitable and Lifts 2025 Outlook but What Will Sustain Growth? - Sahm
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript - Insider Monkey
Xeris raises 2025 revenue guidance to $285M-$290M as RECORLEV revenue more than doubles year-over-year - MSN
Xeris Biopharma Holdings, Inc. (2B30.F) stock price, news, quote and history - Yahoo Finance Singapore
Xeris Biopharma Hits Day Low at $7.00 Amid Price Pressure - Markets Mojo
Xeris Biopharma Holdings Inc (XERS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 - BioSpace
Assessing Xeris Biopharma (XERS) Valuation Following Strong Q3 Earnings and Raised Revenue Guidance - simplywall.st
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):